HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

about

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

Item

http://www.wikidata.org/entity/Q51795590

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

@en

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

@nl

type

Item

label

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

@en

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

@nl

prefLabel

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

@en

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

@nl

P1476

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

@en

P2093

Giovanni Gaudino

http://www.w3.org/2001/XMLSchema#string

Haining Yang

http://www.w3.org/2001/XMLSchema#string

Michele Carbone

http://www.w3.org/2001/XMLSchema#string

P2860

Role of extracellular signal-regulated protein kinases in apoptosis by asbestos and H2O2

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Identification of the ron gene product as the receptor for the human macrophage stimulating protein

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor

RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP

Germline mutations in BAP1 predispose to melanocytic tumors

Germline BAP1 mutations predispose to malignant mesothelioma

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species.

MET: a critical player in tumorigenesis and therapeutic target

P304

327-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/BIOMEDICINES2040327

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28548074

http://www.w3.org/2001/XMLSchema#string

P932

5344271

http://www.w3.org/2001/XMLSchema#string